Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria

Study Overview
=================
Brief Summary
-----------------
Various treatment options exist for patients with platinum-sensitive relapsed epithelial ovarian cancer (ROC). The register will provide an overview of chosen treatments including the reasons, why these options were chosen.

Detailed Description
-----------------
Patients at their first platinum-sensitive ROC will be invited to participate in the register. These are all patients with recurrent disease 6 or more months after the last cycle of platinum containing chemotherapy. The Observation Period will begin by signing the Informed Consent Form (ICF) and will continue for up to a total of 24 months (+/- 4 weeks) after the diagnosis of the first relapse or until patient discontinuation for any reason, or patient's death. Data on First Study Visit, Subsequent Recurrence during Observation Period and Last Observation will be collected in the electronic Case Report Form (eCRF). The register will identify symptoms and factors that led to the diagnosis, chosen therapy and the reason for choosing the therapy. At inclusion, data on general patient information, primary diagnosis, previous therapy, and tumor characteristics are collected. During the course of observation data on systemic and maintenance treatments, radiotherapies, surgeries, and outcome are documented.

Official Title
-----------------
Non-interventional, Multicenter, Prospective Register Study to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer (ROC) Patients in Austria

Conditions
-----------------
Recurrent Ovarian Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women aged 18 years or older Presence of first platinum-sensitive ROC (ovarian, peritoneal and/or fallopian tube cancer) Must have received at least 4 cycles of chemotherapy during primary therapy At time of inclusion a treatment for ROC must be planned Patients must not have more than 1 prior line of chemotherapy Signed informed consent Exclusion Criteria: No knowledge of spoken and written German Signed informed consent is not given

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess treatment patterns and the reasons for selecting these treatments in patients with platinum-sensitive ROC after first relapse in Austria | Descriptive Data Analysis | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression Free Survival | after first relapse and second relapse, evaluated by clinical practice in each center | 2 years per patient | 
| Overall Survival | at 24 months | 2 years per patient | 
| Assess Treatments | treatment duration, number of cycle, treatment exposure, time to next treatment | 2 years per patient | 
| Overall Survival Description | died due to disease, died due to other reasons, alive | 2 years per patient |